Risk Factors for Denosumab Discontinuation in Patients with Postmenopausal Osteoporosis.
Kyosuke HattoriNobunori TakahashiToshihisa KojimaShiro ImagamaPublished in: Modern rheumatology (2022)
A low BMI, low serum Alb levels, and a high number of VFs were associated with denosumab discontinuation in patients with PMO.